U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Center for Biologics Evaluation and Research Dashboard
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Center for Biologics Evaluation and Research Dashboard

FDA-TRACK: Biologics
FDA-TRACK Home Page

FDA's Center for Biologics Evaluation and Research (CBER) regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.

CBER’s performance measures reported in the FDA-TRACK Program align to the CBER 2021-2025 Strategic Plan. The CBER Strategic Plan is organized by four goals. Each goal is briefly described below with links to visualizations and dashboards. Explore the progress CBER is making by strategic goal on the FDA-TRACK website.

CBER 2021-2025 Strategic Goals

CBER Goal 1

Goal 1

Facilitate the Development and Availability of Safe and Effective Medical Products Through the Integration of Advances in Science and Technology

Goal 2

Conduct Research to Address Challenges in the Development and Regulatory Evaluation of Medical Products

CBER Goal 2
Goal 3

Goal 3

Increase Preparedness for Emerging Threats and Promote Global Public Health

Goal 4

Manage for Strategic Excellence and Organizational Accountability

CBER Goal 4

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top